Lipid-lowering and anti-inflammatory effect of ezetimibe in hyperlipidemic patients with coronary artery disease

Heart and Vessels

Volumn 28, Issue 1, 2013, Pages 39-45

  Tobaru, Tetsuya ^a   Seki, Atsushi ^a   Asano, Ryuta ^a   Sumiyoshi, Tetsuya ^a   Hagiwara, Nobuhisa ^b  

^a SAKAKIBARA HEART INSTITUTE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Coronary artery disease; Ezetimibe; Hyperlipidemia; Low density lipoprotein cholesterol; Remnant lipoprotein cholesterol

Indexed keywords

ACARBOSE; ADIPONECTIN; AMLODIPINE; ATENOLOL; ATORVASTATIN; C REACTIVE PROTEIN; CANDESARTAN; CARVEDILOL; CHOLESTEROL; CREATINE KINASE; DILTIAZEM; EZETIMIBE; GLIMEPIRIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LIPID; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIFEDIPINE; OLMESARTAN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN; VOGLIBOSE;

AGED; ANGINA PECTORIS; ANTIINFLAMMATORY ACTIVITY; ANTILIPEMIC ACTIVITY; ARTERIOSCLEROSIS; ARTICLE; BODY MASS; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG MECHANISM; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; MALE; METABOLIC SYNDROME X; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERLIPIDEMIAS; INFLAMMATION; LIPIDS; MALE; TREATMENT OUTCOME;

EID: 84872578541     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-012-0243-8     Document Type: Article

References (27)

1. Teramoto T, Kashiwagi A, Mabuchi H (2005) Status of lipid-lowering therapy prescribed based on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults: a study of the Japan Lipid Assessment Program (J-LAP). Curr Ther Res 66:80-95
2. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357
3. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335:1001-1009
5. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP (2003) Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107:2409-2415
6. Miettinen TA, Gylling H, Strandberg T, Sarna S (1998) Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian Simvastatin Survival Study. Finnish 4S Investigators. BMJ 316:1127-1130
7. Strandberg TE, Tilvis RS, Pitkala KH, Miettinen TA (2006) Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly: a prospective study. J Am Coll Cardiol 48:708-714
8. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP (2002) Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 40:2125-2134
9. Olijhoek JK, Hajer GR, van der Graaf Y, Dallinga-Thie GM, Visseren FL (2008) The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. J Cardiovasc Pharmacol 52:145-150
10. Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, Tershakovec AM (2006) Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 22:2041-2053
11. Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH (2010) Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 33:1134-1139
12. Hiramitsu S, Ishiguro Y, Matsuyama H, Yamada K, Kato K, Noba M, Uemura A, Yoshida S, Matsubara Y, Kani A, Hasegawa K, Hishida H, Ozaki Y (2010) The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. J Atheroscler Thromb 17:106-114
13. Yoneda M, Fujita K, Nozaki Y, Endo H, Takahashi H, Hosono K, Suzuki K, Mawatari H, Kirikoshi H, Inamori M, Saito S, Iwasaki T, Terauchi Y, Kubota K, Maeyama S, Nakajima A (2010) Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study. Hepatol Res 40:613-621
14. Nozue T, Michishita I, Ito Y, Hirano T (2008) Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia. J Atheroscler Thromb 15:146-153
15. Ellsworth JL, Kraemer FB, Cooper AD (1987) Transport of beta-very low density lipoproteins and chylomicron remnants by macrophages is mediated by the low density lipoprotein receptor pathway. J Biol Chem 262:2316-2325
16. Kugiyama K, Doi H, Motoyama T, Soejima H, Misumi K, Kawano H, Nakagawa O, Yoshimura M, Ogawa H, Matsumura T, Sugiyama S, Nakano T, Nakajima K, Yasue H et al (1998) Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation 97:2519-2526
17. Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y, Tsunoda R, Sakamoto T, Nakano T, Nakajima K, Ogawa H, Sugiyama S, Yoshimura M, Yasue H et al (1999) Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 99:2858-2860
18. Nozue T, Michishita I, Mizuguchi I (2010) Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. J Atheroscler Thromb 17:37-44
19. Pearson TA, Ballantyne CM, Veltri E, Shah A, Bird S, Lin J, Rosenberg E, Tershakovec AM (2009) Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol 103:369-374
20. Yagi S, Akaike M, Aihara K, Iwase T, Ishikawa K, Yoshida S, Sumitomo-Ueda Y, Kusunose K, Niki T, Yamaguchi K, Koshiba K, Hirata Y, Dagvasumberel M, Taketani Y, Tomita N, Yamada H, Soeki T, Wakatsuki T, Matsumoto T, Sata M (2010) Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. J Atheroscler Thromb 17:173-180
21. Azar RR, Badaoui G, Sarkis A, Azar M, Aydanian H, Harb S, Achkouty G, Kassab R (2010) Effect of ezetimibe/atorvastatin combination on oxidized low density lipoprotein cholesterol in patients with coronary artery disease or coronary artery disease equivalent. Am J Cardiol 106:193-197
22. Chen JW, Chen YH, Lin SJ (2006) Long-term exposure to oxidized low-density lipoprotein enhances tumor necrosis factor-alpha-stimulated endothelial adhesiveness of monocytes by activating superoxide generation and redox-sensitive pathways. Free Radic Biol Med 40:817-826
23. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M (2003) Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 34:2349-2354
24. Matsuo T, Iwade K, Hirata N, Yamashita M, Ikegami H, Tanaka N, Aosaki M, Kasanuki H (2005) Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia. Heart Vessels 20:8-12
25. Hongo M, Tsutsui H, Mawatari E, Hidaka H, Kumazaki S, Yazaki Y, Takahashi M, Kinoshita O, Ikeda U (2008) Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study. Cir J 72:722-728
26. Takahashi Y, Satoh M, Tabuchi T, Nakamura M (2011) Prospective, randomized, single-blind comparison of effects of 6 months' treatment with atorvastatin versus pravastatin on leptin and angiogenic factors in patients with coronary artery disease. Heart Vessels. doi: 10.1007/s00380-011-0156-y
27. Oka H, Ikeda S, Koga S, Miyahara Y, Kohno S (2008) Atorvastatin induces associated reductions in platelet P-selection, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases. Heart Vessels 23:249-256